Articles On MGC Pharmaceuticals (ASX:MXC)

ShareCafeStocks of the Hour: REC, MXC, SOP                    Recharge Metals (ASX:REC) has entered into a binding agreement to acquire 100% of the Express Lithium Project in the prolific James Bay Region of Canada. Commenting on the...

15 Mar 2023 - A snapshot of the stocks on the move featuring Recharge Metals (ASX:REC), MGC Pharmaceuticals (ASX:MXC) and Synertec Corporation (ASX:SOP).

MGC Pharmaceuticals (MXC) completes its in-vitro pre-clinical study on its anti-inflammatory test drug, CimetrA The company says the study confirms previous trial results that showed CimetrA significantly decreases inflammation MGC C...

Emyria partners with PAX to provide safe MDMA-based psychedelics therapy for PTSD MGC Pharma concludes that IL-32 mRNA plays an important role in tumour inflammation   Emyria collaborates with Pax on PTSD Clinical stage biotech company Em...

MGC Pharma completes pre-clinical study on CimetrA Recce Pharma close to getting Aussie patent AdAlta gets second patent in Japan   MGC Pharma on track for FDA submission MGC Pharma (ASX:MXC) has completed the full pre-clinical rodents st...

The ASX is poised to open higher on the first day of 2023 Wall Street had one of its worst years in 2022 IMF warns of a tougher year   Aussie shares are set to advance on the first trading day of the year. At 8am AEDT, the ASX 200 Jan fut...

NSB files new patent in Australia Imugene doses first patient in Phase 1 trial Cronos and MGC Pharma give sales update   NSB announces patent filing in Australia NeuroScientific Biopharma (ASX:NSB) announced a new patent filing in Austral...

The ASX is set to rise on Monday Wall Street finished mixed after a strong jobs report lifted the risk of higher Fed rates OPEC+ decided to keep output steady The ASX is set to open higher on Monday ahead of the RBA interest rates call to...

Aussie market delivers a rock-solid mediocre effort Koba Resources hits the jackpot by hammering some tent pegs into the dirt Thank the heavens, not much has changed since lunchtime   It’s not been a record-breaker by any stretch of the i...

The ASX 200 starts the week with a bang Materials surge has investors beaming China learns a brutal lesson about leadership from Hong Kong It’s the end of the day, and we’re all clearly super-happy because it’s been a positive run for Aus...

Three medicinal cannabis companies — two of which are based in WA — have been hit with fines totalling nearly $1 million over alleged unlawful advertising.

While early days, MGC Pharmaceuticals is encouraged by interim results in the CimetrA dose finding study, key to moving the drug towards marketing authorisation as a registered medicine. European based Biopharma MGC Pharmaceuticals (ASX:MXC...

Researchers say data shows transition from illicit to legal use of cannabis Medicinal users are at 37%, compared to 2.5% in 2018 Regulations, quality control and costs still barriers for legal week users   New research from the University...

MGC Pharmaceuticals (MXC) receives a US$1 million (A$1.43 million) order for its anti-inflammatory product, ArtemiC The order comes after the company updated its US Supply and Distribution agreement with AMC to include its ArtemicC product...

The ASX200 is riding Wall Street’s coattails today up 044% Nine out of eleven sectors were higher, with real estate leading the charge Technology was a close second with the help of a unicorn takeover bid   Wall Street rallied on Friday a...

Ice-T is opening a cannabis dispensary in New Jersey this year Snoop Dogg’s venture capital firm led a seed funding round for TSUMo Snacks Incannex ramps up development and manufacturing of IHL-216A drug New Jersey has given Ice-T the gre...

MGC Pharma believes ZAM is a game-changer and has the possibility of personalising medication  – not just with cannabis-based drugs, but with all pharmaceutical drugs. European based Biopharma MGC Pharmaceuticals (ASX:MXC) (LON:MXC) has tak...

Investors have reacted positively to news MGC Pharma’s ArtemiC has shown promise in treating Long Covid, which is afflicting millions of people globally.   European based Biopharma MGC Pharmaceuticals (ASX:MXC) (LON:MXC) has announced succ...

MGC Pharmaceuticals (MXC) receives study and import approvals from the South African Health Products Regulatory Authority for the Phase IIb CimetrA trial The trial will aim to target the effects of viral infections with inflammatory compli...

MGC Pharma to go Phase 2 on COVID-19 in South Africa Neurotech says cannabis strain works well in children with Autism Spectrum Disorder Nova Eye’s revenue impacted by China lockdowns MGC Pharma set to start Phase IIb trial in South Afric...

MGC Pharmaceuticals (ASX:MXC) has provided an update on its pre-clinical in vitro study of CimetrA.

MGC Pharmaceuticals (MXC) indicates CimetrA has a wide-ranging application as an anti-inflammatory treatment Results from a study demonstrated the product could be used for more than purely the treatment of COVID-19, which had been the pri...

MGC Pharma is working to provide treatment hope for one of the most common and aggressive forms of brain cancers with an early study showing positive signs they’re on the right track. Aussie-listed biopharma MGC Pharmaceuticals (ASX:MXC) h...

A Thai university says adding cannabis to chicken feed has positive results on meat and egg quality Aussie cannabis campaigner now a Member of the Order of Australia MGC Pharma’s CBD treatment proves effective against brain tumors   Chian...

MGC Pharmaceuticals (MXC) completes a successful in-vitro preclinical research study in the use of cannabinoids to treat glioblastoma The study was undertaken between 2019 and 2022, initially using a formulation that included THC but was l...

Emerging Companies (XEC) index jumps more than 2% before trimming gains   Benchmark ASX200 down 0.15% Greentech Metals up over 120%, in trading halt   Inspired by strength in gold and metals Aussie small caps have bounced off the canvas...

Actor Woody Harrelson has opened a cannabis store in West Hollywood Releaf has plans for a weed wellness retreat in Byron Bay Incannex wants to buy out APIRx   It’s not surprising that Woody Harrelson loves weed – the actor was actually...

MGC Pharmaceuticals (MXC) has been granted a patent from the Slovenian Intellectual Property Office (SIPO) for CimetrA The patent provides MGC with commercial protection over the intellectual property regarding the formation and manufactur...

LONDON, April 5, 2022 /PRNewswire/ – MGC Pharmaceuticals Ltd. (LSE: MXC, ASX: MXC, OTC:MGCLF), a European based bio-pharma company specializing in the production and development of phytomedicines, has signed an exclusive distribution agr...

V-Con is Stockhead’s investing focused video conference series, bringing you expert insights, panel discussions and presentations from leading analysts, listed small caps and industry players. Global cannabis sales could hit $35 billion in...

MGC Pharma has just delivered its best half ever, as it looks to complete a pipeline of clinical trials and convert them into commercial contracts. The half saw MGC Pharma (ASX:MXC) achieve its strongest half-year result to date, with total...

The ASX 200 Health Index (XHJ) is trading higher by 0.55% at the time of writing, compared to the broader index which is up by 0.45%. Cannabis stock Avecho Biotechnology (ASX:AVE) announced today that patient dosing has commenced for its Ph...

Sales amounted to US$1.8mln in the fourth quarter, with COVID-19 treatment ArtemiC accounting for 60% of the total

The MGC Pharmaceuticals Ltd (ASX: MXC) share price smoked the market today. This comes after the company provided investors with a positive update regarding its clinically tested nutritional supplement, ArtemiC Rescue. At the closing bell,...

The ASX has recovered following yesterday’s strong blow, closing up 1.29% with all 11 sectors finishing in the green on lower than normal trading volumes. Today’s biggest sector win was energy, up a nice 2.20% with the financial market foll...

MGC Pharmaceuticals (MXC) receives an import approval permit for its COVID-19 treatment product, ArtemiC Rescue, into India The drug underwent a small batch trial import, passing all required regulatory motions to enable the sale of the pr...

Managing director Roby Zomer says MGC is “pleased to have the opportunity to alleviate the symptoms of COVID-19 in one of the largest populated countries in the world”

It’s been another year of lockdown and supply challenges for all companies dealing with the COVID-19 variants as they pop up. But with challenges, comes opportunities to learn and grow. So as the end of the year approaches, we took the chan...

It’s been another year of lockdown and supply challenges for all companies dealing with the COVID-19 variants as they pop up. But with challenges, comes opportunities to learn and grow. So as the end of the year approaches, we took the chan...

It’s been another year of lockdown and supply challenges for all companies dealing with the COVID-19 variants as they pop up. But with challenges, comes opportunities to learn and grow. So as the end of the year approaches, we took the chan...

MGC Pharmaceuticals (MXC) begins a clinical study on patients with Long COVID syndrome in Spain MGC Pharma is co-sponsoring the study, along with partners Swiss PharmaCan AG and Glow LifeTech, which will investigate the efficacy of its sup...

It’s been another year of lockdown and supply challenges for all companies dealing with the COVID-19 variants as they pop up. But with challenges, comes opportunities to learn and grow. So as the end of the year approaches, we took the chan...

Swiss PharmaCan and Glow LifeTech are carrying out the research which should be complete in February

The TGA nod is the first ever in Australia. A breakthrough which gives MGC Pharma partner EXTRAX credibility, access and a huge head start into a unique market. Note the date, the Therapeutics Goods Administration (TGA) has just approved Au...

It said it plans to begin the approval process for CimetrA in India before rolling it out to a total of five countries in central and eastern Europe and central Asia

The ASX returned to positive territory today as investors began to shrug off fears of the omicron variant, but the bourse is still well below levels seen last week. While utilities lost over 1%, most other sectors gained with telcos being t...